First AD

Second AD

Balazs Halmos, MD, is the director of Thoracic Oncology and the director of Clinical Cancer Genomics at Albert Einstein College of Medicine, Montefiore Einstein

Panelists discuss how the FLAURA, FLAURA2, and MARIPOSA trials have reshaped first-line therapy for EGFR-mutant non–small cell lung cancer. FLAURA established osimertinib as superior to first-generation tyrosine kinase inhibitors. FLAURA2 showed added benefit with chemotherapy. MARIPOSA highlighted amivantamab-lazertinib as a strong alternative, refining treatment choices.

FLAURA, FLAURA2, and MARIPOSA: Key Takeaways to Impact First-Line Treatment Approach

Video content above is prompted by the following: 

Can you walk us through how the FLAURA, FLAURA2, and MARIPOSA data have influenced your approach to first-line therapy? What aspects of these trials were most compelling?

FLAURA: Ramalingam SS, et al. ESMO 2019. Abstract LBA5_PR. J. Soria, FLAURA_NEJM_2017,

MARIPOSA: M. Campelo ESMO 2024 Abstract 5M0, E. Felip ASCO 2024 Abstract 8504

Video Series

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 